ExodusPoint Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

ExodusPoint Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-800	Closed	-$33K	–	2189
2023 Q1	$33K	Buy	+800	New	+$37.6K	﹤0.01%	1678
2022 Q2	–	Sell	-432	Closed	-$16K	–	2372
2022 Q1	$16K	Sell	432 -66	-13%	-$4.13K	﹤0.01%	2110
2021 Q4	$49K	Sell	498 -231	-32%	-$24.9K	﹤0.01%	2033
2021 Q3	$91K	Buy	+729	New	+$88K	﹤0.01%	1917
2021 Q2	–	Sell	-659	Closed	-$89K	–	2732
2021 Q1	$89K	Sell	659 -193	-23%	-$24K	﹤0.01%	1992
2020 Q4	$77K	Buy	+852	New	+$73.9K	﹤0.01%	1856
2020 Q2	–	Sell	-1,077	Closed	-$78K	–	1990
2020 Q1	$78K	Buy	1,077 +618	+135%	+$59.7K	﹤0.01%	920
2019 Q4	$33K	Buy	+459	New	+$22.1K	﹤0.01%	1459

Other funds holding RNAC

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's RNAC Position: Q2 2023 in Review

ExodusPoint Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 800 shares — an estimated $33K sold.

ExodusPoint Capital Management first reported a position in RNAC in Q4 2019 and held it in 8 quarters. The position peaked at $91K in Q3 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

ExodusPoint Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 800 Cartesian Therapeutics shares in Q2 2023, an estimated $33K.
ExodusPoint Capital Management first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 8 quarters.
ExodusPoint Capital Management's Cartesian Therapeutics position peaked at $91K in Q3 2021.
92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.